Ozonated Oil Emulsion for Seborrhea in Women (OOSE)
A Randomized, Double-Blind, Placebo-Controlled Trial of an Ozonated Oil-Based Emulsion With Biotin for Seborrhea Management: Chemical Characterization, Stability Profiling, and Clinical Efficacy in Adult Women
This study evaluates a new ozonated oil-based hair cream for women with oily scalp (seborrhea). The cream contains natural oils (moringa, wheat germ, olive, and chili extract) treated with ozone, plus biotin (vitamin B7).
66 women aged 18-40 years participated in this 6-week study. Participants were randomly assigned to receive either:
- The active cream (ozonated oils + biotin), OR
- A placebo cream (without active ingredients)
Neither the participants nor the researchers knew which cream was given (double-blind). Participants applied the cream to their scalp every evening for 6 weeks.
The main goal was to measure changes in scalp oil (sebum) production at Week 6 compared to baseline. Other outcomes included hair manageability, shine, and scalp comfort.
Results showed that the active cream significantly reduced scalp oil by 28% compared to 10% in the placebo group. The cream was well-tolerated with only mild side effects (scalp irritation in 6% of active group).
This study suggests that ozonated oil emulsion may be a safe and effective cosmetic option for managing oily scalp in women.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
BACKGROUND:
Seborrheic scalp conditions affect 3-5% of adults, causing excessive oiliness and social discomfort. Current treatments use synthetic surfactants that may damage hair and scalp barrier. Ozonated oils represent a "green chemistry" approach that modifies natural oils to create bioactive compounds with antimicrobial and sebum-regulating properties.
INTERVENTION:
The study product is a low oil-in-water emulsion containing:
- Ozonated oil blend (7%): Moringa oleifera, Triticum vulgare, Olea europaea, Capsicum annuum oleoresin
- Biotin (0.1%): Vitamin B7 for keratin synthesis
- Placebo: Identical base without ozonated oils and biotin
STUDY DESIGN:
Single-center, randomized, double-blind, placebo-controlled parallel-group trial conducted at Al-Manara University, Syria (February-May 2024).
PARTICIPANTS:
66 adult women (18-40 years) with objective sebum ≥200 μg/cm² and self-reported daily hair washing due to oily scalp. Female-only enrollment to minimize sex-based variability in sebum production.
PRIMARY ENDPOINT:
Percent change from baseline in sebumeter-measured scalp sebum content at Week 6.
SECONDARY ENDPOINTS:
Hair manageability, shine, scalp comfort (0-10 scales), and Investigator Global Assessment.
STATISTICAL ANALYSIS:
ANCOVA on Week 6 absolute values with baseline covariate, following FDA guidance on covariate adjustment. Sensitivity analyses included MMRM and per-protocol.
KEY FINDINGS:
Active treatment showed 28.5% sebum reduction vs. 9.8% placebo (difference:
-18.7%, 95% CI: -22.0 to -15.5, p<0.0001), exceeding the 15% clinically meaningful threshold. All secondary endpoints favored active treatment.
LIMITATIONS:
Single-center, female-only, 6-week duration. Generalizability to males and long-term safety require further study.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Aleppo, Syria
- Clinical Research Unit, Syrian Scientific Society for Medicinal Herbs, Aleppo
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Female sex (biological), ages 18-40 years
- Objective sebum measurement ≥200 µg/cm² at baseline (Sebumeter SM 815)
- Self-reported daily or near-daily hair washing due to oily scalp
- Willing to abstain from other hair treatments for 2-week washout and study duration
- Signed informed consent
Exclusion Criteria:
- Active scalp dermatoses (psoriasis, atopic dermatitis, tinea capitis) requiring medical treatment
- Known hypersensitivity to study ingredients or fragrance components
- Pregnancy, lactation, or planned pregnancy during study period
- Systemic medications affecting sebum production (isotretinoin, hormonal contraceptives initiated within 3 months, anti-androgens)
- Participation in other cosmetic or pharmaceutical trials within 30 days
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Ozonated oil-based cosmetic emulsion
Low oil-in-water emulsion containing ozonated natural oils (Moringa oleifera, Triticum vulgare, Olea europaea, Capsicum annuum oleoresin) plus biotin 0.1%.
Applied 5g to scalp evening, overnight, rinsed morning for 6 weeks.
|
Low oil-in-water emulsion containing ozonated natural oils (Moringa oleifera 3%, Triticum vulgare 1.95%, Olea europaea 2%, Capsicum annuum oleoresin 0.05%) plus biotin 0.1%.
Applied 5g to scalp evening, overnight, rinsed morning for 6 weeks.
Andre navn:
|
|
Annen: Matched vehicle control
Identical base formulation with caprylic/capric triglyceride and isopropyl palmitate to match total oil phase (8%), rheology, and cosmetic elegance.
Same application protocol: 5g evening, overnight, 6 weeks.
|
Identical base formulation with caprylic/capric triglyceride 6% and isopropyl palmitate 2% to match total oil phase (8%), rheology, and cosmetic elegance.
Same application protocol: 5g evening, overnight, 6 weeks.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent change from baseline in scalp sebum content measured by Sebumeter
Tidsramme: Baseline (Day 0) and Week 6
|
Objective measurement of scalp sebum production using Sebumeter SM 815 (Courage+Khazaka, Germany).
Three standardized sites (vertex, left and right parietal regions) measured and averaged.
Negative values indicate sebum reduction.
Pre-specified clinically meaningful threshold: 15% absolute reduction.
|
Baseline (Day 0) and Week 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hair shine score (investigator-rated)
Tidsramme: Baseline, Week 2, Week 4, Week 6
|
Standardized 10-point scale via standardized lighting and photography.
Higher scores indicate improved shine.
|
Baseline, Week 2, Week 4, Week 6
|
|
Scalp comfort score (participant-reported)
Tidsramme: Baseline, Week 2, Week 4, Week 6
|
Standardized 10-point scale (1=severe discomfort, 10=complete comfort).
Higher scores indicate improved comfort.
|
Baseline, Week 2, Week 4, Week 6
|
|
Investigator Global Assessment success rate
Tidsramme: Week 6
|
5-point categorical scale dichotomized as success (clear/almost clear) versus failure (mild/moderate/severe).
Assessed in per-protocol population with complete Week 6 data.
|
Week 6
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse event rate
Tidsramme: Throughout 6-week study period
|
Number and severity of adverse events assessed via standardized query, severity grading (mild/moderate/severe), and causality assessment.
|
Throughout 6-week study period
|
|
Scalp irritation score
Tidsramme: Week 2, Week 4, Week 6
|
Scalp irritation assessed at each visit via participant self-report with severity grading.
|
Week 2, Week 4, Week 6
|
|
Product adherence percentage
Tidsramme: Throughout 6-week study period
|
Compliance assessed via returned product weighing (expected use: 35 g/week) and electronic diary entries.
|
Throughout 6-week study period
|
|
Treatment compliance rate
Tidsramme: Throughout 6-week study period
|
Percentage of expected product use calculated from returned product weight.
Threshold: ≥80% compliance.
|
Throughout 6-week study period
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Hisham M Kasem, Prof., Syrian Scientific Society for Medicinal Herbs
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- SHAMNA-2024-008
- SSS-008-2024 (Registeridentifikator: Syrian Scientific Society for Medicinal Herbs (SHAMNA))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ANALYTIC_CODE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .